Consensus statement on the need for innovation, transition and implementation of developmental neurotoxicity (DNT) testing for regulatory purposes.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Fritsche, EllenGrandjean, Philippe
Crofton, Kevin M
Aschner, Michael
Goldberg, Alan
Heinonen, Tuula
Hessel, Ellen V S
Hogberg, Helena
Bennekou, Susanne Hougaard
Lein, Pamela J
Leist, Marcel
Mundy, William R
Paparella, Martin
Piersma, Aldert H
Sachana, Magdalini
Schmuck, Gabriele
Solecki, Roland
Terron, Andrea
Monnet-Tschudi, Florianne
Wilks, Martin F
Witters, Hilda
Zurich, Marie-Gabrielle
Bal-Price, Anna
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Consensus statement on the need for innovation, transition and implementation of developmental neurotoxicity (DNT) testing for regulatory purposes.Published in
Toxicol Appl Pharmacol 2018; advance online publication (ahead of print)Publiekssamenvatting
This consensus statement voices the agreement of scientific stakeholders from regulatory agencies, academia and industry that a new framework needs adopting for assessment of chemicals with the potential to disrupt brain development. An increased prevalence of neurodevelopmental disorders in children has been observed that cannot solely be explained by genetics and recently pre- and postnatal exposure to environmental chemicals has been suspected as a causal factor. There is only very limited information on neurodevelopmental toxicity, leaving thousands of chemicals, that are present in the environment, with high uncertainty concerning their developmental neurotoxicity (DNT) potential. Closing this data gap with the current test guideline approach is not feasible, because the in vivo bioassays are far too resource-intensive concerning time, money and number of animals. A variety of in vitro methods are now available, that have the potential to close this data gap by permitting mode-of-action-based DNT testing employing human stem cells-derived neuronal/glial models. In vitro DNT data together with in silico approaches will in the future allow development of predictive models for DNT effects. The ultimate application goals of these new approach methods for DNT testing are their usage for different regulatory purposes.PMID
29447839ae974a485f413a2113503eed53cd6c53
10.1016/j.taap.2018.02.004
Scopus Count
Collections